secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001193125-24-157839
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa appoints John Crowley as CFO, Gregory Weinhoff as Chief Business Officer
--------------------------------------------------------------------------------

- John Crowley appointed CFO effective June 10, 2024; replaces Gregory Weinhoff who becomes CBO.
- Crowley receives $525k base salary, 40% target annual bonus, and option to purchase 600,000 ADSs.
- Crowley previously CFO of Fusion Pharmaceuticals (acquired by AstraZeneca) and Merus, plus finance roles at Charles River, Ironwood, Vertex.
- Weinhoff moves from CFO to newly created CBO role; he co-founded Arvelle Therapeutics and led in-licensing of cenobamate.
- No family relationships or related-party transactions disclosed between Crowley and the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312524157839/0001193125-24-157839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312524157839/d793909d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-157839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer